🟢 Citius Pharmaceuticals is trading 8.91% up in pre-market — no clear company-specific catalyst identified

Citius Pharmaceuticals is trading 8.91% up at $0.61 after no clearly disclosed company-specific catalyst was identified for September 16, 2026.

• Management presented at the H.C. Wainwright conference on September 15, discussing LYMPHIR commercialization and Mino-Lok’s FDA review.
• Available coverage does not explicitly connect the presentation to the pre-market move.
• Broader futures are modestly higher ahead of the Federal Reserve decision, offering limited market support.